Gilead Raises 2026 Sales Outlook
Gilead Sciences raised its full-year sales outlook after reporting third-quarter revenue and earnings that beat Wall Street estimates. The company noted strong growth in its flagship HIV drug franchise despite looming Medicare price cuts.
Xurve View
Insights:
Xurve View
Gilead Sciences raised its full-year sales outlook to $31.3 billion on Thursday after reporting a 13% rise in third-quarter product sales. The drugmaker beat Wall Street expectations, driven by a surge in its flagship HIV drug franchise. That growth comes despite an upcoming 38% price cut for its top treatment in the United States.
